Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors or multiple myeloma, which compared XGEVA to Zometa in preventing skeletal-related events.

23 Feb 2011

Cerasome filled molecular-sized bubbles to target liver cancer cells

Nanotechnology may open a new door on the treatment of liver cancer, according to a team of Penn State College of Medicine researchers. They used molecular-sized bubbles filled with chemotherapy drugs to prevent cell growth and initiate cell death in test tubes and mice.

23 Feb 2011

American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer

Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

23 Feb 2011

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 2 portion of the trial of IPI-926 in combination with gemcitabine in patients with previously untreated, metastatic, pancreatic cancer.

22 Feb 2011

Caution on mammograms for breast cancer survivors: Study

A new study finds that in women who have had breast cancer, annual mammograms help detect second breast cancers, but they are not as effective in women who have never had the disease.

22 Feb 2011

Educational intervention may increase awareness about kidney transplant recipients' risk of developing skin cancer

Sharing printed educational materials about the risk of squamous cell carcinoma with kidney transplant recipients appeared to be effective at increasing skin self-examination and encouraging follow-up with a dermatologist to determine risk of cancer, according to a report posted online today that will appear in the June issue of Archives of Dermatology, one of the JAMA/Archives journals.

22 Feb 2011

John Theurer chief to present videos on new limb-sparing surgical techniques at AAOS conference

James C. Wittig, M.D., chief of the division of skin and sarcoma cancer at the John Theurer Cancer Center at Hackensack University Medical Center will present eleven different educational videos on innovative approaches to orthopedic oncology at the upcoming American Academy of Orthopaedic Surgeons Conference.

20 Feb 2011

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has signed a licensing agreement with Biocare Medical, a biotechnology company based in Concord, Calif., for the exclusive worldwide sales and distribution rights for the immunohistochemistry of an antibody designed to detect tumor prevalence in prostate cancer patients.

18 Feb 2011

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started.

18 Feb 2011

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Exelixis, Inc. today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial.

18 Feb 2011

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Endo Pharmaceuticals and Bioniche Life Sciences Inc. today announced plans for peer-reviewed presentation of interim efficacy and safety results from the first Phase III trial of the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin™ or EN3348.

18 Feb 2011

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Biosciences, Inc., announced today that it is currently in discussions with the U.S. Food and Drug Administration ("FDA") relating to the PrevOnco™ Special Protocol Assessment ("SPA") Phase III protocol submitted by the Company in December 2010.

18 Feb 2011

Two researchers receive Brupbacher Prize for Cancer Research 2011

Today, the Charles Rodolphe Brupbacher Prize for Cancer Research 2011 goes to two researchers who have contributed to better understanding of the genetics underlying the growth of tumors.

17 Feb 2011

Continued smoking during radiation treatment for head and neck cancer affects prognosis

Smokers who continue to smoke while undergoing radiation treatments for head and neck cancer fare significantly worse than those who quit smoking before therapy, according to a study in the February issue of the International Journal of Radiation Oncology•Biology•Physics, an official journal of the American Society for Radiation Oncology (ASTRO).

17 Feb 2011

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

17 Feb 2011

Smoking during radiation treatments reduces chance of overall survival

Smokers who continue to smoke while undergoing radiation treatments for head and neck cancer fare significantly worse than those who quit smoking before therapy, according to a study in the February issue of the International Journal of Radiation Oncology·Biology·Physics, an official journal of the American Society for Radiation Oncology (ASTRO).

16 Feb 2011

Scientists to present research on RMI ability to classify lung, kidney tumors at USCAP meeting

Clinical researchers from Cornell Weil Medical School and University of Chicago Medical School will present research conducted on Raman Molecular Imaging's ability to differentiate diagnostic dilemmas in lung and kidney tumors at the United States and Canadian Academy of Pathology's 100th Annual Meeting, Feb. 26-March 4 at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

16 Feb 2011

Study: Active wound healing can lead to increased risk of basal cell carcinoma in skin

Processes that are involved in active wound healing can lead to an increased risk for basal cell carcinoma in the skin. This is the conclusion of a recent study from the Swedish medical university Karolinska Institutet, published in the journal PNAS.

15 Feb 2011

Neoprobe achieves accrual goal in Lymphoseek Phase 3 study in breast cancer/melanoma

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that a multi-center Phase 3 study of Lymphoseek® has enrolled clinical subjects to achieve the minimum analysis goal of 196 lymph nodes, the study's primary accrual objective.

14 Feb 2011

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

AVEO Pharmaceuticals, Inc. today announced that previously reported positive clinical data evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC) will be featured in several poster presentations at the American Society of Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium being held February 17-19, 2011 at the Orlando World Center Marriott in Orlando, Fla.

14 Feb 2011

Carcinoma News and Research

Further Reading

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Cerasome filled molecular-sized bubbles to target liver cancer cells

American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Caution on mammograms for breast cancer survivors: Study

Educational intervention may increase awareness about kidney transplant recipients' risk of developing skin cancer

John Theurer chief to present videos on new limb-sparing surgical techniques at AAOS conference

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Two researchers receive Brupbacher Prize for Cancer Research 2011

Continued smoking during radiation treatment for head and neck cancer affects prognosis

Astellas, AVEO enter development, commercialization agreement for tivozanib

Smoking during radiation treatments reduces chance of overall survival

Scientists to present research on RMI ability to classify lung, kidney tumors at USCAP meeting

Study: Active wound healing can lead to increased risk of basal cell carcinoma in skin

Neoprobe achieves accrual goal in Lymphoseek Phase 3 study in breast cancer/melanoma

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News